ArticleProbiotics and antimicrobial proteins2026
Comprehensive Phenotypic and Genomic Study for Understanding the Variability in Susceptibility of Listeria monocytogenes to AMPs and Bacteriocins.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In this study, we investigated the inhibitory activity of six antimicrobial peptides against 40 Listeria monocytogenes isolates from clinical, environmental, or food samples. Antibiotic susceptibility assays revealed high resistance to clindamycin, whereas resistance to ciprofloxacin was less frequent. Additionally, four isolates were resistant to at least one or two antibiotics. Virulome analysis revealed that the prfA-virulence gene cluster, the main pathogenicity determinant marker in Listeria monocytogenes (prfA, plcA, plcB, hly, mpl and actA) was detected in selected strains. The anti-listeria activities of the bacteriocins, bactofencin A (M14L, M18L), nisin Z, pediocin PA-1 (M31L) and plantaricin S, as well as two lipopeptides, brevibacillin and its synthetic analog brevibacillin Thr1 were assessed. These molecules were selected based on their structural diversity and distinct mechanisms of action. All peptides displayed inhibitory activity against all isolates with a minimal inhibitory and bactericidal concentrations ranging between 0.54 µM and 18.20 µM. In general, the antimicrobial activity of these peptides was not associated with the antibiotic resistance profile or the presence/absence of virulence genes. To elucidate the observed variability in susceptibility, a comparative genomic and structural impact analysis were performed. These revealed polymorphisms occurring in several genes associated with stress response, efflux pumps, membrane and protein biosynthesis. These polymorphisms could help to explain the decreased susceptibility profiles of certain isolates. Overall, through their diversity in structure and mechanism of action, these peptides have been shown to be powerful inhibitors of L. monocytogenes and could serve as alternative to conventional antibiotics for the control of this pathogen.
Indexed as
Identifiers
42446768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.